SCHEDULE: Vanguard Group Reports 0% Beneficial Ownership in Agios

The Vanguard Group has amended its Schedule 13G, reporting 0% beneficial ownership in Agios Pharmaceuticals Inc due to an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 10 to its Schedule 13G for Agios Pharmaceuticals Inc.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Agios Pharmaceuticals Inc common stock.
• This change is attributed to an internal realignment within The Vanguard Group, effective January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update. The change in reported beneficial ownership by The Vanguard Group is due to an internal realignment and disaggregated reporting, not a direct change in investment thesis for Agios Pharmaceuticals Inc.

Future Outlook

No forward-looking statements or guidance regarding Agios Pharmaceuticals Inc's operations or financial performance are provided in this administrative filing.

Management Comments

• The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors holding more than 5% of a company's stock. An amendment like this, indicating a reduction to 0% beneficial ownership by a major fund manager like Vanguard, typically signals an internal restructuring of reporting responsibilities rather than a complete divestment of all underlying holdings by Vanguard's broader family of funds. This disaggregation allows individual Vanguard entities to report their holdings separately.

Stakeholder Impact

• Shareholders of Agios Pharmaceuticals Inc should be aware that The Vanguard Group, as a single reporting entity, no longer reports beneficial ownership of their common stock, though other Vanguard entities may still hold shares and report them separately.

Key Dates

Keywords

Schedule 13G, Vanguard Group, Agios Pharmaceuticals, Beneficial Ownership, Internal Realignment, Institutional Investor, Common Stock